Cancer antigen 125, usually called CA-125, is a protein found on the surface of certain cells throughout your body. When a blood test measures CA-125, it’s looking for how much of this protein is circulating in your bloodstream. The standard cutoff is 35 U/mL (units per milliliter), though some researchers argue the true normal upper limit is closer to 20 U/mL. An elevated result doesn’t automatically mean cancer, and a normal result doesn’t rule it out.
Where CA-125 Comes From
CA-125 is a piece of a larger protein called MUC16, which sits on the surface of cells lining several organs. Your ovaries, fallopian tubes, uterus, and the membranes surrounding your lungs, heart, and abdominal cavity all naturally produce it. Because so many different tissues make this protein, its levels can rise for reasons that have nothing to do with cancer.
Why Your Doctor Ordered the Test
CA-125 is most commonly associated with ovarian cancer, but it’s not used as a routine screening test for the general population. The U.S. Preventive Services Task Force specifically recommends against screening asymptomatic women with CA-125, because the test doesn’t reduce ovarian cancer deaths and false positives can lead to unnecessary surgeries.
Instead, the test is typically ordered in a few specific situations. If you have a pelvic mass that showed up on imaging, an elevated CA-125 helps your doctor estimate the likelihood that it’s cancerous, especially if you’re postmenopausal. If you’ve already been diagnosed with ovarian cancer, the test tracks whether treatment is working. And if you’ve finished treatment, regular CA-125 checks can flag a possible recurrence.
Non-Cancerous Causes of Elevated Levels
A long list of benign conditions can push CA-125 above the 35 U/mL threshold:
- Endometriosis
- Uterine fibroids
- Pelvic inflammatory disease
- Liver disease
- Menstruation
- Pregnancy and delivery
Hormonal shifts alone can cause noticeable fluctuations. CA-125 levels tend to rise during the premenstrual phase and are higher in women with irregular ovulation. During pregnancy, levels generally stay below 35 U/mL, but they climb during delivery and keep rising for about 48 hours afterward. If your blood was drawn during your period or shortly after giving birth, that context matters when interpreting the number.
Cancers Linked to Elevated CA-125
Ovarian cancer is the condition most closely tied to CA-125, but elevated levels also show up in cancers of the lung, pancreas, stomach, bladder, and liver, as well as in some blood cancers like leukemia and non-Hodgkin’s lymphoma. Fluid buildup around the lungs (pleural effusion) from various causes can raise it too. This is one reason a single CA-125 number can’t point to a specific diagnosis on its own. It’s a clue, not a conclusion.
How CA-125 Tracks Treatment Response
For women already diagnosed with ovarian cancer, CA-125 becomes one of the most useful tools for monitoring chemotherapy. A steady drop in levels reassures both patient and doctor that the tumor is responding. In patients who respond well to treatment, CA-125 levels typically return to normal by the fourth chemotherapy cycle. If the number rises during treatment instead, that can signal drug resistance, prompting a switch to a different approach.
After treatment ends, a high CA-125 reading suggests residual disease may still be present. Even small changes carry meaning: research indicates that a 5% decrease from post-surgery levels suggests stable disease, while an increase of more than about 10% may point to progression and warrants follow-up imaging. When cancer does return, CA-125 levels tend to rise 5 to 6 months before symptoms or scans reveal the recurrence. That lead time gives doctors a window to plan next steps, though earlier detection of recurrence hasn’t always translated into better outcomes in clinical trials.
Why One Number Isn’t Enough
A single CA-125 reading has real limitations. The test has good sensitivity for advanced ovarian cancer but misses a significant portion of early-stage cases. It also lacks specificity, meaning many things besides cancer can trigger a high result. That combination of missing early cancers and flagging benign conditions is exactly why it fails as a population-wide screening tool.
To improve accuracy, doctors sometimes combine CA-125 with a second blood marker called HE4, plugging both values into a formula known as the ROMA index (Risk of Ovarian Malignancy Algorithm). This calculation also factors in whether you’re pre- or postmenopausal. The ROMA index has a sensitivity of about 89% and specificity of about 75%, outperforming either marker alone. Your doctor may use this approach when trying to determine whether a pelvic mass is likely benign or malignant before surgery.
What Your Result Means in Practice
If your CA-125 came back elevated, the number needs context. Your doctor will consider your age, menopausal status, symptoms, imaging results, and medical history before drawing any conclusions. A premenopausal woman with endometriosis and a CA-125 of 50 U/mL is in a very different situation than a postmenopausal woman with a pelvic mass and the same number.
If your CA-125 is normal, that’s generally reassuring but not a guarantee. Some ovarian cancers, particularly early-stage or certain subtypes, don’t produce enough of the protein to raise blood levels above the cutoff. The trend over time matters more than any single snapshot. A level that was 15 and is now 30, even though both readings fall under 35, could still warrant attention depending on the clinical picture.